Intravitreal Bevacizumab Is Associated With Prolonged Ventilatory Support in Preterm Infants With Bronchopulmonary Dysplasia
Journal
Chest
Journal Volume
162
Journal Issue
6
Date Issued
2022-12
Author(s)
Huang, Cho-Yi
Chen, Mei-Huei
Cardoso, Wellington V
Abstract
Intravitreal bevacizumab (IVB), an anti-vascular endothelial growth factor (VEGF) antibody, is a widely adopted treatment for retinopathy of prematurity (ROP). Although animal studies have demonstrated that IVB inhibits alveologenesis in neonatal rat lung, the clinical influence of IVB on respiratory outcomes has not been studied.
Subjects
bronchopulmonary dysplasia; intravitreal bevacizumab; retinopathy of prematurity; vascular endothelial growth factor
SDGs
Type
journal article